What is CritiTech?
CritiTech operates as a sophisticated Contract Development and Manufacturing Organization (CDMO) that serves as a vital link in the pharmaceutical supply chain. By leveraging proprietary technologies such as Purcision supercritical precipitation and advanced spray drying, the firm addresses complex formulation challenges that often impede the commercialization of new therapeutics. Their service portfolio spans the entire development lifecycle, from early-stage pre-formulation and particle engineering to comprehensive analytical services and full-scale manufacturing. With a legacy spanning over 125 years, the company combines deep technical expertise with a collaborative approach, enabling pharmaceutical partners to accelerate the transition of life-changing medications from the laboratory to the patient. Their market position is defined by a commitment to precision and quality, making them an essential partner for firms navigating the increasingly rigorous demands of modern drug development.
How much funding has CritiTech raised?
CritiTech has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in CritiTech
PPP
Public-Private Partnership
What's next for CritiTech?
The infusion of capital from this late-stage financing round is expected to catalyze the next phase of CritiTech's growth strategy. By prioritizing the expansion of its proprietary particle engineering platforms, the company aims to enhance its throughput and technical versatility. Strategic focus will likely shift toward increasing capacity for high-potency manufacturing and strengthening its analytical service offerings to meet the evolving needs of the biopharmaceutical industry. As the firm continues to integrate its advanced precipitation technologies into broader clinical pipelines, it remains poised to capture additional market share, solidifying its reputation as a premier provider of outsourced pharmaceutical solutions. Future initiatives will likely emphasize operational efficiency and the scaling of infrastructure to support the growing demand for specialized drug delivery systems.
See full CritiTech company page
